- GSK reported an adjusted EPS of 23.2p, surpassing the estimate of 20.4p.
- Total revenue came in at GBP8.12 billion, beating the expected GBP7.9 billion.
- Specialty Medicines sales totaled GBP3.30 billion, ahead of the GBP3.24 billion estimate.
- Vaccines sales reached GBP2.21 billion, slightly below the estimate of GBP2.25 billion.
- General Medicines sales were GBP2.61 billion, exceeding the estimated GBP2.47 billion.
- Shingrix generated GBP848 million, surpassing its projection of GBP840.8 million.
- Arexvy revenue fell short at GBP158 million compared to an expected GBP251.6 million.
- Bexsero revenue was significantly higher at GBP227 million against a forecast of GBP164.2 million.
- Flixotide/Flovent brought in GBP143 million, outperforming the expected GBP87.7 million.
- Relvar/Breo Ellipta revenue was slightly below estimate at GBP275 million against GBP282.8 million.
- Advair/Seretide revenue exceeded expectations at GBP259 million compared to GBP235.5 million.
- Trelegy Ellipta generated GBP669 million, marginally below the estimate of GBP676.4 million.
- Xevudy reported GBP11 million against a negative projection of -GBP0.74 million.
- Triumeq revenue was GBP346 million, surpassing the estimate of GBP337.1 million.
- Tivicay revenue came in at GBP343 million, beating the projected GBP313 million.
- Dovato sales totaled GBP638 million, surpassing the GBP597.7 million expectation.
- Juluca revenue was slightly higher than forecasted at GBP189 million against GBP186.9 million.
- Nucala generated GBP484 million, underperforming the estimate of GBP516 million.
- Benlysta revenue was GBP423 million, below the estimated GBP439.5 million.
- Zejula revenue of GBP143 million was less than the expected GBP161.3 million.
- The adjusted operating margin stood at 17.6%, slightly below the estimate of 18.2%.
- R&D expenses were higher than expected at GBP1.82 billion versus GBP1.73 billion.
- General and administrative expenses were lower than anticipated at GBP2.70 billion against an estimate of GBP2.73 billion.
- GSK raised its 2031 sales target to over £40 billion from the previous target of more than £38 billion, adjusted for risk and at CER.
- The company maintained its 2026 core operating profit margin expectation of more than 31%.
- Analyst ratings include 8 buys, 13 holds, and 4 sells.
“`
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, has received a mixed bag of SmartKarma Smart Scores for its long-term outlook. With above-average scores in Dividend and Growth, indicating a solid dividend payout and moderate growth potential, the company shows promise in these areas. However, lower scores in Value and Resilience suggest that there may be challenges in terms of undervaluation and resilience to market fluctuations. Momentum, with a mid-range score, hints at a steady but not rapid pace of growth for the company. Overall, while GlaxoSmithKline PLC demonstrates strengths in dividends and growth, there are areas where improvements could bolster its long-term prospects.
GlaxoSmithKline PLC offers a range of products in the pharmaceutical sector, including vaccines, prescription drugs, over-the-counter medicines, and health-related consumer products. The company’s portfolio spans various medical fields, such as infections, depression, skin conditions, asthma, heart and circulatory diseases, and cancer. With a diversified product line catering to different health needs, GlaxoSmithKline PLC plays a significant role in the healthcare industry. The SmartKarma Smart Scores provide valuable insights into different aspects of the company’s performance, highlighting both strengths and areas for potential enhancement in its long-term trajectory.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
